首页> 外文OA文献 >Magselectofection: A novel integrated technology of magnetic separation and genetic modification of target cells
【2h】

Magselectofection: A novel integrated technology of magnetic separation and genetic modification of target cells

机译:magselectofection:一种新的磁分离和靶细胞遗传修饰的整合技术

摘要

Research applications and cell therapies involving genetically modified cells require reliable, standardized and cost-effective methods for cell manipulation. The goal of this work is to provide a novel methodology that produces, in a single standardized techonology, genetic modification and cell isolation. We have named this novel procedure ―Magselectofection”. The approach is based on magnetic cell separation and magnetically-guided gene delivery (magnetofection). Optimized gene vectors associated with novel magnetic nanoparticles were formulated to transfect/transduce target cells while they are passaged and separated through a high gradient magnetic field cell separation column. Magnetofection of the Jurkat T cells using selected vector formulations resulted in a significant (up to 4.5-fold) enhancement in both luciferase reporter gene expression and the percentage of cells expressing eGFP, as compared to lipofection. A procedure for vector loading on LS Miltenyi columns was developed that enables up to 100% retention for both non-viral and viral magnetic complexes. We demonstrate, using a model cell mixture of K562 and Jurkat T cells, that the integrated method is highly efficient and specific for the target cell population. This was not only true for the model Jurkat/K562 mixture, but also for Sca-1+ mouse hematopoietic stem cells. With human umbilical cord mesenchymal stem cells (hUC-MSCs), we achieve up to 30% transfected cells with non-viral vector doses as low as 8 pg plasmid DNA per cell and up to 100% transduced cells with a multiplicity of infection of 0.5 TU/cell using lentivirus. Similarly, we obtain 22% eGFP-positive human cord blood hematopoietic stem cells (hCB-HSCs) upon lentiviral magselectofection compared to 0.15% eGFP-positive cells post-standard infection. We achieve up to 50% transduced Sca-1+ mouse stem cells at a lentiviral MOI of 1-3. Up to 5-15% and 20% genetic modified PBMC were found using non-viral and viral magselectofection, respectively. After genetic modification using magselectofection differentiation potential of hCB-HSCs and hUC-MSCs was maintained. Magselectofection requires a minimal number of manipulation steps and results in efficient and specific gene delivery to target cells. This minimizes the necessary vector material while maintaining the cellular differentiation potential of modified stem cells. Magselectofection may become a useful tool for nucleic acid therapy approaches involving ex-vivo genetically modified cells.
机译:涉及转基因细胞的研究应用和细胞疗法需要可靠,标准化和具有成本效益的细胞操作方法。这项工作的目的是提供一种新颖的方法,以单一的标准化技术产生基因修饰和细胞分离。我们将这种新颖的过程命名为“ Magselectofection”。该方法基于磁性细胞分离和磁性引导的基因递送(磁转染)。配制与新型磁性纳米粒子相关的优化基因载体,以在目标细胞通过高梯度磁场细胞分离柱进行传代和分离时转染/转导目标细胞。与脂转染相比,使用选定的载体制剂对Jurkat T细胞进行磁转染可导致萤光素酶报告基因表达和表达eGFP的细胞百分比显着提高(最多4.5倍)。开发了一种在LS Miltenyi色谱柱上进行载体上样的方法,该方法可以使非病毒和病毒磁性复合物的保留率高达100%。我们证明,使用K562和Jurkat T细胞的模型细胞混合物,该集成方法是高效且对目标细胞群体具有特异性的。这不仅适用于Jurkat / K562模型混合物,而且适用于Sca-1 +小鼠造血干细胞。使用人脐带间充质干细胞(hUC-MSC),我们可以实现高达30%的转染细胞,其中非病毒载体剂量低至8 pg质粒DNA /细胞,以及高达100%的转导细胞,感染复数为0.5使用慢病毒的TU /单元。同样,慢病毒磁选择感染后,我们获得22%eGFP阳性的人脐血造血干细胞(hCB-HSCs),而标准感染后为0.15%eGFP阳性细胞。我们在1-3的慢病毒MOI上实现了高达50%的Sca-1 +小鼠干细胞转导。使用非病毒和病毒磁选择转染分别发现高达5-15%和20%的基因修饰PBMC。使用磁选择转染进行基因修饰后,保持了hCB-HSC和hUC-MSC的分化潜能。磁选择转染需要最少的操作步骤,并能有效且特异性地将基因递送至靶细胞。这将必需的载体材料减至最少,同时保持了修饰干细胞的细胞分化潜能。磁选择转染可能成为涉及体外转基因细胞的核酸治疗方法的有用工具。

著录项

  • 作者

    Sanchez Antequera Yolanda;

  • 作者单位
  • 年度 2010
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号